Bring Clarity to
a complex disease

Advanced Technologies to better characterize
and assess cancer

GE Healthcare Biopharma Services

Pharma Services

NeoGenomics offers lab services for oncology clinical trials

Learn more 

Clarient Client Resources

For current Clarient clients only, access your Clarient resources here.

Browse Resources


Welcome to our new website!

Your resource for the combined NeoGenomics
and Clarient companies

August 29 - September 2, 2016 - Boston, MA

Visit Us at Booth 20

S U M M I T   2 0 1 6


PD-L1 Updates

SP142 for bladder cancer now available

Learn more


HER-2 Breast FISH Alternative Assessment

The July-December 2016 self-assessment for our tech-only FISH clients is ready.

Sign into NeoUniversity™

New Tests

Ventana PD-L1 (SP142) Assay, an FDA approved complementary diagnostic in metastatic urothelial carcinoma.

Indicated as an aid in identifying patients most likely to benefit from TECENTRIQ®


Learn more

Comprehensive detection of sarcoma transocations by next-gen sequencing to enhance diagnosis, subclassification, and treatment

Learn more

NGS Comprehensive Sarcoma Fusion Profile

Targeted next-gen sequencing panel that detects significant translocations in the genes NTRK1, NTRK3, and RET

Learn more

NGS Thyroid Fusion Profile